Member Info for sicilian_kan

Thanks MF11, that's a much more helpful response. Much appreciated.

I know it is ahead of schedule. It says that in the RNS. That was not my question. My question was when do people expect it to be finished. That is a different question to the one you have sardonically answered.

Very good, but yes, in all seriousness, when do people expect the exploration decline (do I really need to define this further!) to be finished.

When are people expecting the decline to be finished?

Frauds usually come out of the woodwork at times of global financial stress. No different to things like Stanford International and Madoff coming out of the credit crunch.

Even more so now! I cannot see how they are still trading.

This is also worth a read:

hTTps://www.realbusinessrescue.co.uk/company-administration/what-are-the-exit-routes-out-of-company-administration

Yes, the subsidiaries can be sold and the proceeds would be controlled by the administrators. The order of payment is:

1. Secured creditors:
2. Preferential Creditors such as Employees and HMRC
3. Fixed and floating charges:
4. Fixed charge creditors:
5. Floating charge creditors:
6. Unsecured creditors:
7. Connected unsecured creditors:
8. Shareholders

You don't own the subsidiary. The holding company does and that is now controlled by the administrators.

If they were prioritising a placing, they would be doing a roadshow with presentation after presentation at all the usual places. We would know about that if it were happening.

Excellent find from Gibson on Telegram!

Why would they need to recruit for a “quarterly forecast process” and “for quarterly FP&A P&L and Cashflow forecasting” if they are just going to continue with research only sales that tick over in small annual sums? Why would they recruit for this post if not expecting substantial revenues?

One more point. Quarterly reporting is what NASDAQ requires…

That said what is being sought is not quarterly reporting but quarterly forecasting…which clearly implies significant cash flow. I think AGL are very confident they are now moving to significant revenues.

Candle Stick on Telegram was helpfully looking at the data from the FDA's website on de novo applications, in their November 2021 report. In the coming days the latest quarterly statistics will be out.

I've now gone through some of the back issues. The data is very illuminating. What stands out for me is as follows:

If you look at the [Jan-Dec] 2019 de novo submissions (i.e. all those submitted in the calendar year before Angle's, to give a comparison), then you can see the following.

- The success rate for the slowest determined applications (those determined after the December 2020 report) was 80% compared to 46% for all 2019 submitted de novo applications. This can be seen by comparing the data from the December 2020 report to the data from the November 2021 report, by when all applications had been determined.

- Having your submissions take a long time to be determined is therefore a very good thing as it suggests a very high chance of success in the de novo application.

hTTps://www.fda.gov/industry/medical-device-user-fee-amendments-mdufa/mdufa-reports

Daniel Morgan

Okay, thank you. You highlighted ground conditions that Havieron and speeding progress to-date on that decline. Can you expand on this, is that just near surface this issue has arised or is it an issue, you think, an ongoing issue?

Sandeep Biswas

We were always anticipating issues in as you get through the first 400 meters of cover. And what we are finding as we started to decline, those conditions were worse than we imagined. I mean, you can only do limited cuts before you had to shore it all up again. Otherwise, you would have the materials for the real round the side.

So that slowed us down a lot that we change the design a little bit. So we were going to go on a decline straight if you can, straight but at a decline, and then step down to the next level, we have brought that forward where we are now going down in the spiral earlier in the decline, and then continue to decline after that.

This is to try and get through that 400 meters of cover as soon as we possibly can, and get into the better ground conditions. So we can start accelerating. Now exactly what the impact all of that is, we are working through an out, but that is fundamentally the issue that we have encountered.

There is no flu pandemic, yet in the UK over 19 million people received the flu vaccine pre Covid in the 2019-2020 season. If we vaccinate the vulnerable against the flu, we will surely do so for covid too each winter and that alone is a staggering ongoing revenue opportunity.

Vaccination rates in South Africa are low. Only 32.7% have had at least one dose. Yes, there are lots of people there who have now had Covid, and that will reduce the pool, but there will be enough people in South Africa to meet the remaining 24 people planned for the trial.

Just to put this into perspective, when the Covidity news that they had merely developed the vaccine was announced, stating they intended to put Covidity into trials in 2021 (which later happened), the share price shot up from 14p to 30p, before dropping back down to the 20-22p region.

We are now back to 17.75p mid, almost back to where we started, despite Covidity now being in trials, having been proven to be safe in 16 patients, and with partnership planned once the data comes out this half year.

Each one of these is massive progress over last year. And we also have SCIB1 first patient dosed, which we did not have then, and Modi-1 due to start trials this half too. Cash levels are very good with no need for dilution. We have also had a supportive board with a connected party buying when the sp fell below 19p.

All in all, I think the fall unjustified. I understand that people will drift out when there are delays, but these are small delays and with Covidity recruitment due to pick up as the RNS says, it won't be that long before we get a recruitment complete RNS from Covidity and the landscape will change in (in the grand scheme of things) very little time.

P.S. Fully appreciate the labs are going to target ovarian as their first test, not MBC and that for MBC, the route being pursued is the FDA route.

Correction it is in the CTC Isolation section that follows the Materials and Methods section, but the quote from the article and the timing point I make is the same.

Hi Bermuda, thanks as ever for your excellent research and for sharing this link with us. I've now tracked down the full text here in case of interest: https://link.springer.com/content/pdf/10.1245/s10434-021-11135-2.pdf

The results are very interesting and promising, albeit as you note the numbers were small. My amateur reading is that only 4 of the 19 patients were assessed six months later.

One more point that I have noticed, was the following in the Materials and Methods section:

"As processing time is critical to maximize capture efficiency total time from blood draw to CTC harvest did not exceed 2 h".

Whilst the results received certainly are very impressive, albeit on a small sample size, adopting a 2 hour process from blood draw to harvesting to maximise results is not at all feasible commercially at the moment or reflective of what would happen in reality when sending blood draws across the country (or continent) to Angle's labs for testing.

I know the ultimate strategy is to get Parsortix into a large number of hospitals for routine use but that is certainly not realistic in the short or medium term and is also dependent upon FDA approval.

That the share price is just 13.9p-14.3p this evening shows just what a joke the 37p share price high was. Ramped until kingdom come by people who (whether through knowledge or ignorance) pumped the share price and shut down any shareholders with a different view. Now the share price is just 13.9p-14.3p. For a decent return a year ago it should have been no higher than 10p to reflect the current share price, even assuming the current share price is justified.